Mereo BioPharma Group

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MREO and other ETFs, options, and stocks.

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). 

CEO
Denise Vera Scots-Knight
CEODenise Vera Scots-Knight
Employees
36
Employees36
Headquarters
London, Greater London
HeadquartersLondon, Greater London
Founded
2015
Founded2015
Employees
36
Employees36

MREO Key Statistics

Market cap
67.75M
Market cap67.75M
Price-Earnings ratio
-1.61
Price-Earnings ratio-1.61
Dividend yield
Dividend yield
Average volume
3.34M
Average volume3.34M
High today
$0.4543
High today$0.4543
Low today
$0.4151
Low today$0.4151
Open price
$0.4356
Open price$0.4356
Volume
2.45M
Volume2.45M
52 Week high
$3.05
52 Week high$3.05
52 Week low
$0.20
52 Week low$0.20

MREO News

TipRanks 5d
Mereo BioPharma Receives Nasdaq Minimum Bid Price Notice

The latest announcement is out from Mereo Biopharma Group Plc ( (MREO) ). On February 17, 2026, Mereo BioPharma received notice from Nasdaq that its American D...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.